Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (111875) 111875
Publication (8683) 8683
Patent (1797) 1797
Book Review (524) 524
Book Chapter (490) 490
Conference Proceeding (487) 487
Book / eBook (286) 286
Magazine Article (266) 266
Dissertation (107) 107
Government Document (35) 35
Newspaper Article (28) 28
Report (21) 21
Reference (20) 20
Paper (19) 19
Data Set (18) 18
Trade Publication Article (18) 18
Web Resource (18) 18
Newsletter (4) 4
Journal / eJournal (3) 3
Presentation (3) 3
Technical Report (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (65294) 65294
induction (47920) 47920
female (43420) 43420
index medicus (39436) 39436
male (38964) 38964
animals (29460) 29460
remission induction (27573) 27573
adult (26242) 26242
middle aged (22557) 22557
oncology (18411) 18411
treatment outcome (17168) 17168
aged (15411) 15411
mice (14147) 14147
expression (11319) 11319
cancer (10204) 10204
rats (10115) 10115
apoptosis (10047) 10047
antineoplastic combined chemotherapy protocols - therapeutic use (9210) 9210
hematology (8970) 8970
adolescent (8784) 8784
time factors (8314) 8314
biochemistry & molecular biology (7972) 7972
pharmacology & pharmacy (7673) 7673
research (7490) 7490
immunology (7489) 7489
chemotherapy (7310) 7310
therapy (7189) 7189
care and treatment (6990) 6990
analysis (6818) 6818
retrospective studies (6728) 6728
pregnancy (6562) 6562
activation (6385) 6385
cell biology (6323) 6323
prognosis (6180) 6180
follow-up studies (5850) 5850
cells (5541) 5541
child (5523) 5523
cells, cultured (5420) 5420
combined modality therapy (5248) 5248
gene expression (5189) 5189
dose-response relationship, drug (5163) 5163
proteins (5142) 5142
health aspects (5088) 5088
obstetrics & gynecology (4921) 4921
surgery (4730) 4730
toxicology (4641) 4641
enzyme induction (4606) 4606
young adult (4598) 4598
aged, 80 and over (4412) 4412
enzyme induction - drug effects (4349) 4349
research article (4288) 4288
cell line, tumor (4279) 4279
recurrence (4221) 4221
induction chemotherapy (4183) 4183
inhibition (4165) 4165
apoptosis - drug effects (4125) 4125
transplantation (4080) 4080
multidisciplinary sciences (4027) 4027
ovulation induction (4027) 4027
prospective studies (3990) 3990
medicine, research & experimental (3948) 3948
survival rate (3936) 3936
article (3913) 3913
medicine (3904) 3904
risk factors (3853) 3853
gene-expression (3803) 3803
disease-free survival (3640) 3640
physiological aspects (3636) 3636
survival (3604) 3604
growth (3555) 3555
inflammation (3546) 3546
reproductive biology (3534) 3534
child, preschool (3513) 3513
in-vitro (3501) 3501
cell line (3426) 3426
oxidative stress (3426) 3426
neoplasm staging (3384) 3384
drug administration schedule (3340) 3340
antineoplastic agents - therapeutic use (3301) 3301
disease (3296) 3296
medicine & public health (3274) 3274
survival analysis (3173) 3173
plant sciences (3142) 3142
differentiation (3130) 3130
mice, inbred c57bl (3099) 3099
endocrinology & metabolism (3092) 3092
ovulation induction - methods (3002) 3002
signal transduction (2966) 2966
gastroenterology & hepatology (2955) 2955
medicine, general & internal (2801) 2801
biology (2762) 2762
drug therapy, combination (2746) 2746
tumors (2734) 2734
genetic aspects (2731) 2731
cytokines (2728) 2728
rats, sprague-dawley (2699) 2699
children (2690) 2690
antineoplastic combined chemotherapy protocols - adverse effects (2666) 2666
studies (2665) 2665
radiotherapy (2653) 2653
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (95) 95
Robarts - Stacks (53) 53
UTL at Downsview - May be requested (36) 36
Engineering & Comp. Sci. - Stacks (35) 35
UofT at Mississauga - Stacks (23) 23
St. Michael's College (John M. Kelly) - 3rd Floor (20) 20
UofT at Scarborough - Stacks (17) 17
Victoria University E.J. Pratt - Stacks (16) 16
Online Resources - Online (14) 14
Mathematical Sciences - Stacks (13) 13
OISE - Stacks (13) 13
Physics - Stacks (10) 10
Thomas Fisher Rare Book - Rare Book (10) 10
Collection Dvlpm't (Acquisitions) - Closed Orders (9) 9
Thomas Fisher Rare Book - May be requested at Fisher (7) 7
Collection Dvlpm't (Acquisitions) - Vendor file (6) 6
St. Michael's College (John M. Kelly) - 2nd Floor (5) 5
Trinity College (John W Graham) - Stacks (5) 5
Chemistry (A D Allen) - Stacks (3) 3
Physics - Storage (3) 3
Trinity College (John W Graham) - Storage (3) 3
OISE - May be requested in 6-10 wks (2) 2
OISE - Missing (2) 2
Pontifical Inst. Mediaeval Studies - Library use only (2) 2
UofT at Mississauga - May be requested in 6-10 wks (2) 2
Earth Sciences (Noranda) - Stacks (1) 1
Engineering & Comp. Sci. - Missing (1) 1
Gerstein Science - Missing (1) 1
Knox College (Caven) - Stacks (1) 1
Mathematical Sciences - May be requested in 6-10 wks (1) 1
Mathematical Sciences - Missing (1) 1
Regis College - Stacks (1) 1
Robarts - Searching (1) 1
Royal Ontario Museum - Stacks (1) 1
St. Augustine's Seminary - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UofT at Scarborough - Withdrawn (1) 1
Victoria University E.J. Pratt - Storage (1) 1
Victoria University Emmanuel College - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (107122) 107122
French (2645) 2645
Japanese (1377) 1377
Russian (1055) 1055
German (1026) 1026
Chinese (757) 757
Spanish (633) 633
Polish (393) 393
Italian (205) 205
Portuguese (138) 138
Hungarian (93) 93
Korean (75) 75
Romanian (71) 71
Dutch (68) 68
Czech (59) 59
Bulgarian (56) 56
Ukrainian (35) 35
Danish (21) 21
Serbian (20) 20
Croatian (17) 17
Turkish (17) 17
Persian (14) 14
Hebrew (9) 9
Slovak (9) 9
Arabic (8) 8
Swedish (7) 7
Icelandic (6) 6
Norwegian (6) 6
Slovenian (4) 4
Bosnian (3) 3
Lithuanian (3) 3
Afrikaans (2) 2
Finnish (2) 2
Indonesian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase results from a single-group, phase 2, open-label study
by Mahon, François-Xavier and Boquimpani, Carla and Kim, Dong-Wook and Benyamini, Noam and Clementino, Nelma Cristina D and Shuvaev, Vasily and Ailawadhi, Sikander and Lipton, Jeffrey Howard and Turkina, Anna G and De Paz, Raquel and Moiraghi, Beatriz and Nicolini, Franck E and Dengler, Jolanta and Sacha, Tomasz and Takahashi, Naoto and Fellague-Chebra, Rafik and Acharya, Sandip and Wong, Stephane and Jin, Yu and Hughes, Timothy P
Annals of Internal Medicine, ISSN 0003-4819, 04/2018, Volume 168, Issue 7, pp. 461 - 470
Treatment-free remission (TFR)-that is, stopping tyrosine kinase inhibitor (TKI) therapy without loss of response-is an emerging treatment goal in chronic... 
Drug Administration Schedule | Humans | Middle Aged | Kaplan-Meier Estimate | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Treatment Outcome | Remission Induction | Imatinib Mesylate - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Polymerase Chain Reaction | Aged, 80 and over | Adult | Female | Aged | Nilotinib | Complications and side effects | Care and treatment | Patient outcomes | Dosage and administration | Chronic myeloid leukemia | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)
by Pönisch, W and Mitrou, P S and Merkle, K and Herold, M and Assmann, M and Wilhelm, G and Dachselt, K and Richter, P and Schirmer, V and Schulze, A and Šubert, R and Harksel, B and Grobe, N and Stelzer, E and Schulze, M and Bittrich, A and Freund, M and Pasold, R and Friedrich, Th and Helbig, W and Niederwieser, D and East German Study Group of Hematology and Oncology (OSHO)
Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, 4/2006, Volume 132, Issue 4, pp. 205 - 212
Purpose: This randomized phase III study compared bendamustine and prednisone (BP) to standard melphalan and prednisone (MP) treatment in previously untreated... 
Bendamustine | Medicine & Public Health | Hematology | Multiple myeloma | Melphalan | Internal Medicine | Cancer Research | Oncology | Prednisone | TRIALS | multiple myeloma | melphalan | BONE-MARROW | REMISSION INDUCTION | THERAPY | PHARMACOKINETICS | ONCOLOGY | COMBINATION CHEMOTHERAPY | prednisone | STEM-CELL TRANSPLANTATION | bendamustine | MARROW TRANSPLANTATION | Multiple Myeloma - mortality | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Multiple Myeloma - drug therapy | Melphalan - adverse effects | Time Factors | Treatment Failure | Aged, 80 and over | Adult | Female | Germany, East | Prednisone - administration & dosage | Prednisone - adverse effects | Nitrogen Mustard Compounds - adverse effects | Remission Induction | Disease-Free Survival | Melphalan - administration & dosage | Multiple Myeloma - pathology | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Quality of Life | Aged | Care and treatment | Corticosteroids | Steroids
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo‐controlled trial with a re‐treatment extension
by Reich, K and Ortonne, J.‐P and Gottlieb, A.B and Terpstra, I.J and Coteur, G and Tasset, C and Mease, P
British Journal of Dermatology, ISSN 0007-0963, 07/2012, Volume 167, Issue 1, pp. 180 - 190
Background  Certolizumab pegol (CZP) is a PEGylated antitumour necrosis factor agent. Objectives  To evaluate the efficacy and safety of CZP in patients with... 
TO-SEVERE PSORIASIS | CROHNS-DISEASE | CLINICAL-TRIALS | INFLIXIMAB INDUCTION | DOUBLE-BLIND | PLUS METHOTREXATE | QUALITY-OF-LIFE | OPEN-LABEL EXTENSION | MAINTENANCE THERAPY | INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY | DERMATOLOGY | Antibodies, Monoclonal, Humanized - adverse effects | Recurrence | Certolizumab Pegol | Psoriasis - drug therapy | Double-Blind Method | Dermatologic Agents - administration & dosage | Humans | Immunoglobulin Fab Fragments - adverse effects | Middle Aged | Polyethylene Glycols - adverse effects | Male | Treatment Outcome | Dermatologic Agents - adverse effects | Polyethylene Glycols - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Retreatment | Immunoglobulin Fab Fragments - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Adult | Female | Aged
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica: Multicenter Study of Treatment Efficacy
by Mealy, Maureen A and Wingerchuk, Dean M and Palace, Jacqueline and Greenberg, Benjamin M and Levy, Michael
JAMA Neurology, ISSN 2168-6149, 03/2014, Volume 71, Issue 3, pp. 324 - 330
IMPORTANCE Neuromyelitis optica (NMO) is an inflammatory disease of the optic nerves and spinal cord that leads to blindness and paralysis. Effective... 
AZATHIOPRINE | OPEN-LABEL | THERAPY | SPECTRUM DISORDER | RITUXIMAB | CLINICAL NEUROLOGY | Recurrence | Azathioprine - administration & dosage | Neuromyelitis Optica - drug therapy | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Child, Preschool | Rituximab | Azathioprine - pharmacology | Male | Treatment Outcome | Remission Induction | Young Adult | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - pharmacology | Treatment Failure | Adolescent | Adult | Female | Aged | Retrospective Studies | Antibodies, Monoclonal, Murine-Derived - pharmacology | Mycophenolic Acid - administration & dosage | Child
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Plasma for cancer treatment
by Keidar, M
PLASMA SOURCES SCIENCE & TECHNOLOGY, ISSN 0963-0252, 05/2015, Volume 24, Issue 3, pp. 33001 - 20
Plasma medicine is a relatively new field that grew from research in application of low-temperature (or cold) atmospheric plasmas in bioengineering. One of the... 
cancer therapy | PHYSICS, FLUIDS & PLASMAS | plasma selectivity | JET | NEEDLE | CELL-CYCLE | INDUCTION | OPINION | MODEL | cold atmospheric plasma | DAMAGE | DIAGNOSTICS | Medicine | Nanoparticles | Therapy | State of the art | Computation | Selectivity | Atmospherics | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text European comparative effectiveness research on blended depression treatment versus treatment-as-usual(E-COMPARED): study protocol of a randomized controlled non-inferiority trial in eight European countries
by Kleiboer, A.M and Smit, J and Bosmans, J and Ruwaard, J and Andersson, G and Topooco, N and Berger, T and Krieger, T and Botella, C and Banos, R and Chevreul, K and Araya, R and Cerga-Pashoja, A and Cieslak, R and Rogala, A and Vis, C and isma, S and Van Schaik, A and Kemmeren, L and Ebert, D and Berking, M and Funk, B and Cuijpers, P and Riper, H and Institutet för handikappvetenskap (IHV) and Linköpings universitet and Institutionen för beteendevetenskap och lärande and Filosofiska fakulteten and Psykologi
Trials, ISSN 1745-6215, 2016, Volume 17, Issue 1, p. 387
Background: Effective, accessible, and affordable depression treatment is of high importance considering the large personal and economic burden of depression.... 
Cognitive behavioral treatment (CBT) | Internet-based treatment | Comparative effectiveness research (CER) | EHealth | Depression | Adults | Blended treatment | Cost-effectiveness | ICBT | Randomized controlled trial (RCT) | MEDICINE, RESEARCH & EXPERIMENTAL | PATIENT HEALTH QUESTIONNAIRE | METAANALYSIS | DISORDERS | PSYCHOTHERAPY | MAJOR DEPRESSION | eHealth | CARE | INTERVENTIONS | COGNITIVE-BEHAVIORAL THERAPY | iCBT | EXPECTATIONS | Europe | Humans | Clinical Protocols | Depressive Disorder, Major - therapy | Treatment Outcome | Remission Induction | Depressive Disorder, Major - economics | Depressive Disorder, Major - psychology | Cognitive Therapy - economics | Therapy, Computer-Assisted - economics | Health Care Costs | Comparative Effectiveness Research | Time Factors | Cost-Benefit Analysis | Surveys and Questionnaires | Primary Health Care | Depressive Disorder, Major - diagnosis | Internet | Research Design | Prevention | Usage | Cognitive therapy | Care and treatment | Depression, Mental | Economic aspects | Clinical trials | Management | Psychiatric services | Medical and Health Sciences | Medicin och hälsovetenskap | Hälsovetenskaper | Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi | Health Care Service and Management, Health Policy and Services and Health Economy | Health Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Remission and Residual Symptoms After Short-Term Treatment in the Treatment of Adolescents With Depression Study (TADS)
by KENNARD, BETSY and SILVA, SUSAN and VITIELLO, BENEDETTO and CURRY, JOHN and KRATOCHVIL, CHRISTOPHER and SIMONS, ANNE and HUGHES, JENNIFER and FEENY, NORAH and WELLER, ELIZABETH and SWEENEY, MICHAEL and REINECKE, MARK and PATHAK, SANJEEV and GINSBURG, GOLDA and EMSLIE, GRAHAM and MARCH, JOHN and TADS Team
Journal of the American Academy of Child & Adolescent Psychiatry, ISSN 0890-8567, 12/2006, Volume 45, Issue 12, pp. 1404 - 1411
To ascertain remission rates in depressed youth participating in the Treatment for Adolescents With Depression Study (TADS), a multisite clinical trial that... 
treatment | residual symptoms | depression | remission | Depression | Remission | Treatment | Residual symptoms | COGNITIVE-BEHAVIORAL TREATMENT | PSYCHIATRY | AFFECTIVE-DISORDERS | PSYCHOLOGY, DEVELOPMENTAL | PSYCHOTHERAPY | MAJOR DEPRESSION | COMBINATION | FLUOXETINE | CHILDREN | RELAPSE | THERAPY | PEDIATRICS | PLACEBO-CONTROLLED TRIAL | Attention Span | Behavior Modification | Drug Therapy | Cognitive Restructuring | Pharmacology | Emotional Response | Depression (Psychology) | Outcomes of Treatment | Comparative Analysis | Sleep | Counseling Effectiveness | Adolescents | Symptoms (Individual Disorders) | Severity of Illness Index | Diagnostic and Statistical Manual of Mental Disorders | Cognitive Therapy - methods | Demography | Humans | Depressive Disorder, Major - therapy | Serotonin Uptake Inhibitors - therapeutic use | Male | Combined Modality Therapy | Remission Induction | Time Factors | Adolescent | Female | Depressive Disorder, Major - diagnosis | Fluoxetine - therapeutic use | Depressive Disorder, Major - drug therapy | Care and treatment | Diagnosis | Research | Depression in adolescence
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Treatment of multiple myeloma
by Rajkumar, S. Vincent
Nature Reviews Clinical Oncology, ISSN 1759-4774, 08/2011, Volume 8, Issue 8, pp. 479 - 491
The treatment of multiple myeloma has changed dramatically in the past decade. The increase in the number of active agents has generated numerous possible drug... 
MELPHALAN-PREDNISONE | THALIDOMIDE PLUS DEXAMETHASONE | ONCOLOGY | INDUCTION TREATMENT PRIOR | BONE-MARROW-TRANSPLANTATION | NEWLY-DIAGNOSED MYELOMA | PHASE-III | MONOCLONAL GAMMOPATHY | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | HIGH-DOSE DEXAMETHASONE | Multiple Myeloma - therapy | Combined Modality Therapy | Disease Management | Prognosis | Humans | Antineoplastic Protocols | Care and treatment | Chemotherapy, Combination | Multiple myeloma | Stem cells | Transplantation | Research | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma – A final report
by Gnekow, Astrid K and Walker, David and Walker, David A and Kandels, Daniela and Picton, Susan and Picton, Sue and Giorgio Perilongo and Grill, Jacques and Stokland, Tore and Sandstrom, Per Erik and Sandstrom, Per Eric and Warmuth-Metz, Monika and Pietsch, Torsten and Giangaspero, Felice and Schmidt, René and Faldum, Andreas and Kilmartin, Denise and De Paoli, Angela and De Salvo, Gian Luca and Slavc, Irene and Perilongo, Giorgio and Clausen, Niels and Arola, Mikko and Jonsson, Olafur Gisli and Cruz, Ofelia and Navajas, Aurora and Teijeiro, Anna and Kalifa, Chantal and Raquin, Marie-Anne and Verlooy, Joris and Hans, Volkmar and Scheurlen, Wolfram and Hainfellner, Johannes and Ironside, James and Robson, Keith and Skullerud, Kari and Scheie, David and NN and Ruchoux, Marie-Madeleine and Jouvet, Anne and Figarella-Branger, Dominique and Lellouch-Toubiana, Arielle and Prayer, Daniela and Calderone, Milena and Jaspan, Tim and Bakke, Soren Jacob and Vazquez, Eli and Couanet, Dominique and Kortmann, Rolf D and Diekmann, Karin and Scarzello, Giovanni and Taylor, Roger and Lote, Knut and Giralt, Jordi and Carrie, Christian and Habrand, Jean Louis and Soerensen, Niels and Czech, Thomas and Chumas, Paul and Gustavson, Bengt and Zerah, Michel and Wabbels, Bettina and Pinello, Maria Luisa and Fielder, Alistair and Simmons, Ian and Christoffersen, Terje and Calaminus, Gabriele and Brockmann, Knut and Straeter, Ronald and Ebinger, Friedrich and Hernaiz-Driever, Pablo and Lackner, Herwig and Kennedy, Colin and Glaser, Adam and Stromberg, Bo and Indiano, Jose Ma and Rodary, Chantal and Bouffet, Eric and Frappaz, Didier and Emser, Angela and Stephens, Suzanne and Machin, David and Le Deley, Marie-Cécile and Egeland, Thore and Freemann, Carolyn and Schrappe, Martin and Sposto, Richard and Low Grade Glioma Consortium and of the Low Grade Glioma Consortium and the participating centers and Medicinska fakulteten and Institutionen för klinisk vetenskap and Pediatrik and Umeå universitet
European Journal of Cancer, ISSN 0959-8049, 08/2017, Volume 81, pp. 206 - 225
The use of chemotherapy to manage newly diagnosed low grade glioma (LGG) was first introduced in the 1980s. One randomised trial has studied two- versus... 
Chemotherapy | Low grade glioma | Randomised trial | Childhood | BEVACIZUMAB | PHASE-II | DIENCEPHALIC SYNDROME | OPTIC PATHWAY GLIOMA | CHILDREN | PILOCYTIC ASTROCYTOMAS | ONCOLOGY | RECURRENT | WEEKLY VINBLASTINE | PEDIATRIC-ONCOLOGY | Humans | Induction Chemotherapy - methods | Carboplatin - administration & dosage | Child, Preschool | Etoposide - administration & dosage | Infant | Male | Brain Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Vincristine - administration & dosage | Female | Child | Glioma - drug therapy | Etoposide | Gliomas | Standards | Cancer | Index Medicus | Clinical Trial | Clinical Medicine | Pediatrics | Medical and Health Sciences | Medicin och hälsovetenskap | Pediatrik | Cancer and Oncology | Klinisk medicin | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Relation of early tumor shrinkage (ETS) observed in first‐line treatment to efficacy parameters of subsequent treatment in FIRE‐3 (AIOKRK0306)
by Modest, Dominik P and Stintzing, Sebastian and Fischer von Weikersthal, Ludwig and Decker, Thomas and Kiani, Alexander and Vehling‐Kaiser, Ursula and Al‐Batran, Salah‐Eddin and Heintges, Tobias and Lerchenmüller, Christian and Kahl, Christoph and Seipelt, Gernot and Kullmann, Frank and Scheithauer, Werner and Kirchner, Thomas and Jung, Andreas and Stauch, Martina and von Einem, Jobst Christian and Moehler, Markus and Held, Swantje and Heinemann, Volker and FIRE-3 study investigators and FIRE‐3 study investigators
International Journal of Cancer, ISSN 0020-7136, 04/2017, Volume 140, Issue 8, pp. 1918 - 1925
We explored the association of early tumor shrinkage (ETS) and non‐ETS with efficacy of first‐line and consecutive second‐line treatment in patients with KRAS... 
sequence | colorectal cancer | RAS | bevacizumab | cetuximab | KRAS | early tumor shrinkage | SURVIVAL | MULTICENTER | OPEN-LABEL | OXALIPLATIN | COMBINATION | METASTATIC COLORECTAL-CANCER | CHEMOTHERAPY | ONCOLOGY | FOLFIRI PLUS CETUXIMAB | PHASE-3 TRIAL | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - administration & dosage | Proto-Oncogene Proteins p21(ras) - genetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Treatment Outcome | Remission Induction | Disease-Free Survival | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Cetuximab - administration & dosage | Female | Aged | Colorectal Neoplasms - pathology | Camptothecin - analogs & derivatives | Metastasis | Analysis | Colorectal cancer | Cancer | Shrinkage | Therapy | Parameters | Effectiveness | Colorectal carcinoma | Clinical trials | Survival | Subgroups | Tumors | Metastases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups
by Amadori, S and Suciu, S and Stasi, R and Willemze, R and Mandelli, F and Selleslag, D and Denzlinger, C and Muus, P and Stauder, R and Berneman, Z and Pruijt, J.F.M and Nobile, F and Cassibba, V and Marie, J.P and Beeldens, F and Baila, L and Vignetti, M and Witte, T.J.M. de
Leukemia, ISSN 0887-6924, 2005, Volume 19, Issue 10, pp. 1768 - 1773
The therapeutic activity and toxicity profile of gemtuzumab ozogamicin were assessed in 40 patients >60 years of age with acute myeloid leukemia (AML) who were... 
Acute myeloid leukemia | Elderly | Gemtuzumab ozogamicin | Frail | CELLS | INDUCTION CHEMOTHERAPY | EFFICACY | elderly | frail | IMMUNOCONJUGATE | INTERNALIZATION | THERAPY | acute myeloid leukemia | ONCOLOGY | HEMATOLOGY | ELDERLY-PATIENTS | gemtuzumab ozogamicin | Acute Disease | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Survival Rate | Frail Elderly | Remission Induction | Antibodies, Monoclonal, Humanized | Leukemia, Myeloid - classification | Leukemia, Myeloid - drug therapy | Immunotoxins - therapeutic use | Aged, 80 and over | Female | Aged | Aminoglycosides - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights